Brean Murray Downgrades China Medical (CMED) to Hold; Valuation Call
CMED Hot Sheet
Rating Summary:2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 25 | Down: 12 | New: 36
Brean Murray downgrades China Medical (Nasdaq: CMED) from Buy to Hold.
Brean analyst says, "CMED has exceeded our price target of $20. The stock has performed well and has returned ~80% over the last 2 months. Our proprietary leading indicator now suggests a neutral stance. We are hence lowering our recommendation to Hold."
China Medical Technologies, Inc. is a China-based medical device company that develops, manufactures and markets in-vitro diagnostics (IVD) products using chemiluminescence immunoassay technology, magnetic antibody immunoassay technology and fluorescent in situ hybridization technology.
To see more analyst ratings on CMED Click Here.
Brean analyst says, "CMED has exceeded our price target of $20. The stock has performed well and has returned ~80% over the last 2 months. Our proprietary leading indicator now suggests a neutral stance. We are hence lowering our recommendation to Hold."
China Medical Technologies, Inc. is a China-based medical device company that develops, manufactures and markets in-vitro diagnostics (IVD) products using chemiluminescence immunoassay technology, magnetic antibody immunoassay technology and fluorescent in situ hybridization technology.
To see more analyst ratings on CMED Click Here.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- JPMorgan Downgrades RailAmerica Inc. (RA) to Neutral
- Morgan Stanley Downgrades Green Dot (GDOT) to Equalweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
